The House of Lords Science and Technology Committee continues taking evidence for its inquiry into Life Sciences and the Industrial Strategy. The Committee questions representatives from NHS England, Innovate UK and Catapults.
Purpose of sessions
Sir John Bell’s life science strategy sets out the important role the NHS must play in the UK life sciences sector, including faster adoption of innovative new technologies and treatments. However, there are concerns that the NHS is not ready for this level of innovation with issues including funding, resources and the culture of the NHS.
The Committee explores with the witnesses their views on how NHS England can help successfully implement the objectives of the strategy.
Tuesday 7 November in Committee Room 4A, Place of Westminster
- Dr Ruth McKernan CBE, Chief Executive, Innovate UK
- Chris Molloy, CEO, Medicines Discovery Catapult
- Keith Thompson, CEO, Cell and Gene Therapy Catapult
- Professor Graham Hillier, Strategy and Futures Director at the Centre for Process Innovation (CPI), High Value Manufacturing Catapult
- Ian Dodge, National Director for Strategy and Innovation
- Professor Keith McNeil, Chief Clinical Information Officer Health and Social Care
- Professor Mike Hannay, Managing Director of the East Midlands Academic Health Science Network (AHSN)
- The role of the witnesses’ organisations in the implementation of the strategy
- How academics and NHS clinicians can better collaborate on important research
- The role of commissioners in adoption of innovations and whether NHS Trusts should be offered financial incentives for the adoption of innovations
- How the relationship between UKRI and Innovate UK will help with innovation and commercialisation of science